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Background: The  Awareness of Abdominal Adiposity as a Cardiometabolic Risk Factor Study 
assesses the prevalence of cardiometabolic risk factors in adults with abdominal obesity (waist 
circumference $90 cm in men and $80 cm in women) and evaluates how physicians manage 
these patients.
Methods: This is an observational cross-sectional study. Internists, cardiologists, and 
endocrinologists contributed patients to the study. A standardized questionnaire was completed 
and registered demographics, anthropometric measurements, lab results from the medical 
files, and any treatment utilized to manage dyslipidemia, arterial hypertension, diabetes, and 
cardiovascular disease.
Results: A total of 1312 patients was included. The mean age was 49.3 ± 14.6 years and 
834 (63.6%) were female. The primary reason for the physician consultation was treatment 
of obesity (47.5%), followed by management of arterial hypertension (27.7%), diabetes 
(18.3%), dyslipidemia (14.2%), and cardiovascular disease (7.1%). The majority of patients 
identified excess body weight as a health problem (81.4%). However, patients had lost a mean 
of 4.3 ± 3.5 kg. Only 63.4% of patients with arterial hypertension were on drug therapy. Few of 
them had reached target values for diastolic (24.1%) and systolic/diastolic (13.3%) pressure. 
Less than half of the patients with dyslipidemia were receiving lipid-lowering medication. 
Only 32.2% were at their target low-density lipoprotein cholesterol levels. In patients with 
type 2 diabetes, mean fasting plasma glucose level (8.9 ± 3.4 mmol/L) was above the threshold 
recommended by current guidelines.
Conclusions: The study describes the medical care given to individuals with abdominal obesity 
during daily clinical practice by general practitioners, cardiologists, and endocrinologists in 
urban Mexico. Our data confirm that a large proportion of patients are undertreated. Only a small 
percentage of patients with obesity-related comorbidities reach treatment targets. Interventions 
proven to be effective in the prevention of chronic complications have in general not been 
implemented.
Keywords: abdominal obesity, waist circumference, dyslipidemia, type 2 diabetes, pattern of 
care
Introduction
The importance of abdominal adiposity as a marker for chronic nontransmissible 
diseases is well established.1 Increased waist circumference is a component of several 
diagnostic criteria for the metabolic syndrome.2–4 This clinical parameter is considered 
a standard of care for the adult population.
Until recently, the evidence supporting the importance of abdominal adiposity 
has been derived from studies in European and North American populations.5 Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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The thresholds used in Caucasians lack sensitivity for the 
detection of type 2 diabetes and lipid disorders in non-
Caucasian subjects.6 Multiple papers in Asian, Hispanic, and 
other ethnic groups provide conflicting results regarding the 
diagnostic proficiency of waist circumference.7–9 Despite this, 
the majority accept that this variable is a useful marker for 
the identification of several chronic diseases.10
Few papers have evaluated the pattern of care received 
by patients with abdominal obesity.11 The aim of this study 
is to document the pattern of care received by subjects with 
abdominal adiposity under the management of cardiologists, 
endocrinologists, and primary care physicians.
Patients and methods
The  Awareness of Abdominal Adiposity as a Cardiometabolic 
Risk Factor Study is a survey designed to assess the prevalence 
of cardiometabolic risk factors in a cohort of subjects with 
increased waist circumference. In addition, the study aims 
to evaluate how physicians manage these patients. Data 
were collected prospectively from adults in eight countries 
(Argentina, Chile, Colombia, Egypt, Lebanon, Mexico, 
Saudi Arabia, South Africa). Here, we report the results of 
the patients studied in Mexico.
The participating hospitals and clinics provided a list of 
the active specialists in their outpatient clinics. Internists 
(n = 32), cardiologists (n = 42), and endocrinologists 
(n = 41) were randomly selected from this list and invited 
to participate in the study. All physicians had previously 
participated in clinical trials. They were asked to invite 
the first patient scheduled for consultation that fulfilled the 
inclusion/exclusion criteria during a one-month period. Only 
one patient could be included per consulting day.
This is an observational study. The inclusion criteria of the 
study were outpatients $18 years old with abdominal obesity 
(defined by a waist circumference $90 cm for men and $80 cm 
for women as recommended by the International Diabetes 
Federation4). The exclusion criteria included participation 
in other clinical studies, a life expectancy less than a year, 
conditions causing an increased abdominal circumference 
not related to excess adiposity (eg, ascitis, pregnancy), 
recent admission to a hospital, difficulty understanding the 
questionnaire, or unwillingness to participate.
A standardized questionnaire was completed. The 
questionnaire consisted of two sections: one filled in 
by the physician and the other answered by the patient. 
It included documentation of demographics, anthropometric 
measurements (ie, weight, height, waist, hip and neck 
circumference, and body mass index), lab results from the 
medical file, and any treatment utilized to manage dyslipidemia, 
arterial hypertension, diabetes, and cardiovascular diseases. 
In addition, concomitant medications, smoking habits, and 
alcohol consumption were also included. Anthropometric 
measurements were done using standardized procedures. 
Blood pressure was measured in a seated position. The mean 
of two readings obtained after a resting period of at least 10 
minutes between measurements was used for the analyses.
High blood pressure was defined as a value $140/90 mmHg 
or use of antihypertensive medication. The diagnostic 
threshold was lowered to $130/80 in patients with 
type 2 diabetes. Dyslipidemia was defined as any of the 
following abnormalities: low-density lipoprotein cholesterol 
(LDL-c) $2.6 mmol/L, total cholesterol $5.2 mmol/L, 
triglycerides $1.6 mmol/L, or high-density lipoprotein 
cholesterol (HDL-c) # 1.1 mmol/L in males and #1.3 mmol/L 
in females. Type 2 diabetes was diagnosed using the American 
Diabetes Association’s criteria.12
The human research ethics committee of the participating 
institutions approved the study, and informed consent was 
obtained from all subjects.
Statistical analyses
The number of patients to be included in each physician 
group (cardiology, endocrinology, or primary care physician/
internists) was 384. As a result, 1200 patients were expected 
to be studied in each country. Normally distributed data, 
determined using the Kolmogorov–Smirnov test, were 
expressed as means and standard deviation (±SD), whereas 
variables with a skewed distribution were reported as median 
(min–max). McNemar’s Chi Square, Student’s paired t-test 
or Wilcoxon’s test was used as appropriate for comparison 
between the basal characteristics and the information at 
follow-up visits. Kruskal–Wallis analysis was used to 
evaluate significant differences between specialties. Logistic 
regression analyses was used to identified independent factors 
associated with dyslipidemia, hypertension, fasting plasma 
glucose, type 2 diabetes, cardiovascular diseases, and two or 
more of these cardiovascular risk factors. All analyses were 
performed with SAS (v 8.2; SAS Institute, Inc, Cary, NC).
Results
Participating physicians
A total of 105 physicians participated in the study. They were 
primary care/internists (n = 32, 28.7%), cardiologists (n = 42, 
36.5%), or diabetologists/endocrinologists (n = 41, 35.7%). 
Their mean age was 48.4 ± 8.9 years and 74% (n = 84) were 
male. The age (P = 0.89), time in practice (P = 0.76), the num-Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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ber of patients seen per month (P = 0.07), and the number of 
patients seen for obesity/overweight (P = 0.93) per month did 
not differ significantly between groups (Table 1).
Patients
A total of 1312 patients was included. The mean age was 
49.3 ± 14.6 years and 834 (63.6%) were female. Of the study 
sample, 384 (29.3% of the study sample), 428 (32.6%), and 
500 (38.1%) patients consulted the internists or primary care 
physicians, cardiologists, and endocrinologists/diabetologists 
respectively (Table 2).
The primary reason given by the patients for the physician 
consultation was treatment of obesity (n = 623, 47.5%), 
followed by management of arterial hypertension (n = 363, 
27.7%), diabetes (n = 240, 18.3%), dyslipidemia (n = 186, 
14.2%), and cardiovascular disease (n = 93, 7.1%). Some 
(n = 331, 25.4%) gave two or more reasons for consultation. 
The patient’s follow-up under their current physician was 
greater than five years in 167 (12.8%), less than five years 
in 653 (50.2%), and 481 (37%) were seen for the first time. 
Patients requiring treatment of obesity (64%) or diabetes 
(27%) primarily consulted endocrinologists. Those that 
consulted cardiologists were seeking therapy for arterial 
hypertension (56%), dyslipidemia (21%), or cardiovascular 
disease (17%). Cardiometabolic risk factors rarely occur 
individually. There was a significant overlap between 
diabetes, dyslipidemia, and arterial hypertension.
The number of cardiovascular risk factors did not increase 
significantly with increasing waist circumference (Figure 1). 
However, in women, the prevalence of diabetes (13%–36%, 
P = 0.001) and hypertension (41.3%–62.2%, P = 0.01) was 
shown to increase with abdominal adiposity.
Prevalence and management  
of cardiometabolic risk factors
Obesity
The majority of the participants were either overweight or 
obese. Only 3% of men and 4% of women had a body mass 
index (BMI) , 25 kg/m2. The mean BMI for males and 
females was 31.99 ± 5.01 and 32.66 ± 5.71 kg/m2, respectively. 
The prevalence of obesity was higher in women compared to 
men (65.1% vs 61.2%, P = 0.05). Ten percent of participants 
had a BMI $ 40 kg/m2. Neck circumference was recorded 
in 96.1% (n = 1261) of the study sample, respectively. Men 
had a significantly greater neck circumference compared 
to women (42.4 ± 3.6 cm vs 37.0 ± 3.4 cm, P , 0.001). 
In contrast, the waist circumference was larger in women 
(113.2 ± 12.3 vs 110.5 ± 11.3 cm, P , 0.001).
Table 1 Basal characteristics of physicians evaluated in the study
Characteristic All groups  
(n = 115)
Internists  
(n = 32)
Cardiologist  
(n = 42)
Endocrinologist   
(n = 41)
Age (years) 48.4 ± 8.9 47.2 ± 6.3 48.8 ± 8.5 49.0 ± 10.8
gender*
  Male 84 (73.7%) 24 (75%) 35 (85.4%) 25 (61%)
  Female 30 (26.3%) 8 (25%) 6 (14.6%) 16 (39%)
Time in practice (years) 20.4 ± 9.0 20.6 ± 6.5 20.0 ± 9.9 20.7 ± 9.8
number of patients seen/month 150 (25–1000) 120 (25–400) 150 (40–400) 160 (40–1000)
Patients seen for overweight/obesity 47 (4–89) 45 (4–85) 47 (12–80) 50 (10–89)
Practice location
  Urban 113 (98.3%) 31 (96.9%) 42 (100%) 40 (97.6%)
  Rural 2 (1.7%) 1 (3.1%) 0 (0%) 1 (2.4%)
Type of patients
  Mostly “public” 8 (7.0%) 3 (9.4%) 4 (9.5%) 1 (2.4%)
  Mostly “private” 58 (50.4%) 21 (65.6%) 22 (52.4%) 15 (36%)
  Mixed 49 (42.6%) 8 (25.0%) 16 (38.1%) 25 (61%)
Medical settings*
  hospital 24 (21.6%) 5 (15.6%) 12 (29.3%) 7 (18.4%)
  clinic 12 (10.8%) 3 (9.4%) 5 (12.2%) 4 (10.5%)
  Practice/office 47 (42.3%) 17 (53.1%) 18 (43.9%) 12 (31.6%)
  hospital + clinic 4 (3.6%) 2 (6.3%) 0 (0.0%) 2 (5.3%)
  hospital + practice/office 19 (17.1%) 5 (15.6%) 6 (14.6%) 8 (21.1%)
  clinic + practice/office 1 (0.9%) 0 (0.0%) 0 (0.0%) 1 (2.6%)
  hospital + clinic + practice/office 4 (3.6%) 0 (0.0%) 0 (0.0%) 4 (10.5%)
  Teaching hospital 21 (46.7%) 5 (50.5%) 4 (26.7%) 12 (60.0%)
  hospital (other) 24 (53.3%) 5 (50.0%) 11 (73.3%) 8 (40.0%)
Notes: *n not equal to 115 because of missing information. Data reported in mean ± SD, n (%) or median (min–max).Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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Table 2 Basal characteristics of patients
Characteristic All group  
(n = 1312)
Patients treated  
by internists/general  
practitioners  
(n = 384)
Patients treated  
by cardiologist  
(n = 428)
Patients treated  
by endocrinologist/ 
diabetologist  
(n = 500)
Age (years) 49.3 ± 14.6 48.0 ± 14.6 54.2 ± 14.0 46.0 ± 14.1
gender
  Male 478 (36.4%) 130 (33.9%) 197 (46.0%) 151 (30.2%)
  Female 834 (63.6%) 254 (66.1%) 231 (54.0%) 349 (69.8%)
ethnicity
  Mexican mestizo 1130 (86.1%) 310 (80.7%) 373 (87.1%) 447 (89.4%)
  caucasian 141 (10.7%) 54 (14.1%) 51 (11.9%) 36 (7.2%)
  Other 41 (3.2%) 20 (5.3%) 4 (0.8%) 17 (3.4%)
Follow-up
  First time 481 (37.0) 145 (38.0) 163 (38.6) 173 (34.8)
 # 5 years 653 (50.2) 180 (47.1) 197 (46.7) 276 (55.5)
 . 5 years 167 (12.8) 57 (14.9) 62 (14.7) 48 (9.7)
Primary reason for the visit
  Obesity 623 (47.5) 174 (45.3) 129 (30.1) 320 (64.0)
  hypertension 363 (27.7) 93 (24.2) 240 (56.1) 30 (6.0)
  Diabetes 240 (18.3) 55 (14.3) 52 (12.1) 133 (26.6)
  cardiovascular disease 93 (7.1) 8 (2.1) 74 (17.3) 11 (2.2)
  Dyslipidemia 186 (14.2) 60 (15.6) 90 (21.0) 36 (7.2)
  Other 271 (20.7) 126 (32.8) 55 (12.9) 90 (18.0)
cardiovascular risk factors 1.5 ± 1.1 1.2 ± 1.1 1.9 ± 1.0 1.5 ± 1.2
  none 294 (22.4) 129 (33.6) 43 (10.0) 122 (24.4)
  1 risk factor 380 (29.0) 120 (31.3) 96 (22.4) 164 (32.8)
  2 risk factors 341 (26.0) 70 (18.2) 182 (42.5) 89 (17.8)
 . 2 risk factors 297 (22.6) 65 (16.9) 107 (25.0) 125 (25.0)
Systolic blood pressure (mmhg) 126.8 ± 16.4 125.7 ± 14.9 132.3 ± 17.2 122.8 ± 15.4
Diastolic blood pressure (mmhg) 79.8 ± 9.8 79.0 ± 8.7 82.0 ± 10.2 78.4 ± 10.0
hypertension 703 (53.6) 162 (42.2) 321 (75.0) 220 (44.0)
   cases without diabetes and systolic  
blood pressure ,140 mmhg
763 (80.1) 245 (84.2) 224 (68.5) 294 (88.0)
    cases without diabetes and diastolic  
blood pressure ,90 mmhg
765 (80.4) 249 (85.6) 223 (68.2) 293 (87.7)
Type 2 diabetes 324 (24.7) 72 (18.8) 97 (22.7) 155 (31.0)
  Treatment 299 (92.6) 68 (94.4) 83 (86.5) 148 (95.5)
  Biguanides 228 (76.3) 50 (73.5) 52 (62.7) 126 (85.1)
  Sulfonylureas 139 (46.5) 40 (58.8) 44 (53.0) 55 (37.2)
  insulin 44 (14.7) 10 (14.7) 9 (10.8) 25 (16.9)
  Thiazolinediones 32 (10.7) 15 (22.1) 6 (7.2) 11 (7.4)
  Other 18 (6.0) 5 (7.4) 3 (3.6) 10 (6.8)
Microvascular complications 69 (21.6) 19 (26.4) 17 (17.9) 33 (21.6)
  Retinopathy 19 (27.5) 9 (47.4) 6 (35.3) 4 (12.1)
  nephropathy 16 (23.2) 5 (26.3) 3 (17.6) 8 (24.2)
  neuropathy 49 (71.0) 11 (57.9) 12 (70.6) 26 (78.8)
hbA1c in patients with diabetes (%)
 , 7 146 (58.4) 26 (51.0) 14 (40.0) 106 (64.6)
  7–8 46 (18.4) 14 (27.5) 9 (25.7) 23 (14.0)
 . 8 58 (23.2) 11 (21.8) 12 (34.3) 35 (21.3)
cases with diabetes and systolic  
blood pressure ,130 mmhg
138 (43.0) 24 (33.3) 31 (33.0) 83 (53.5)
cases with diabetes and diastolic  
blood pressure ,80 mmhg
88 (27.4) 23 (31.9) 22 (23.4) 43 (27.7)
Total cholesterol (mmol/L) 5.2 ± 1.3 5.1 ± 1.3 5.4 ± 1.5 5.1 ± 1.2
  cases ,5.2 mmol/L 464 (55.6) 108 (54) 134 (49.3) 222 (61.3)
LDL-c (mmol/L) 3.1 ± 0.9 3.2 ± 0.9 3.3 ± 0.9 2.9 ± 0.9
  cases ,2.6 mmol/L 162 (30.6) 29 (25.4) 49 (26.8) 84 (36.1)
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Table 2 (Continued)
Characteristic All group  
(n = 1312)
Patients treated  
by internists/general  
practitioners  
(n = 384)
Patients treated  
by cardiologist  
(n = 428)
Patients treated  
by endocrinologist/ 
diabetologist  
(n = 500)
hDL-c (mmol/L) 1.1 ± 0.3 1.1 ± 0.3 1.1 ± 0.3 1.1 ± 0.4
  normal males ($1.1 mmol/L) 103 (44.8) 28 (54.9) 43 (47.8) 32 (36.0)
  normal females ($1.3 mmol/L) 102 (32.8) 18 (31.6) 30 (31.3) 54 (34.2)
Triglycerides (mmol/L) 1.8 (0.4–22.5) 1.7 (0.4–10.9) 1.9 (0.4–22.4) 1.6 (0.4–14.8)
  cases ,1.6 mmol/L 346 (44.7) 79 (44.4) 96 (38.2) 171 (49.6)
Dyslipidemia 792 (60.4) 194 (50.5) 286 (66.8) 312 (62.4)
  Treatment 345 (29.7) 74 (22.6) 165 (42.5) 106 (23.7)
  Statins 264 (76.5) 55 (74.3) 135 (81.8) 74 (69.8)
  Fibrates 116 (33.6) 28 (37.8) 43 (26.1) 45 (42.5)
  ezetimibe 60 (17.4) 13 (17.6) 30 (18.2) 17 (16.0)
  Other 9 (2.6) 3 (4.1) 2 (1.2) 4 (3.8)
cardiovascular disease 184 (14.0) 31 (8.1) 101 (23.6) 52 (10.4)
  Treatment 596 (48) 133 (38) 304 (72.9) 159 (33.5)
  ARBs 234 (39.3) 62 (46.6) 121 (39.8) 51 (32.1)
  Diuretics 190 (31.9) 39 (29.3) 107 (35.2) 44 (27.7)
  Beta blockers 224 (37.6) 37 (27.8) 139 (45.7) 48 (30.2)
  ccB 164 (27.5) 28 (21.1) 97 (31.9) 39 (24.5)
Use of weight control treatment 157 (12.1) 48 (13.0) 24 (5.6) 85 (17.1)
  Orlistat 32 (20.4) 14 (29.2) 9 (37.5) 9 (10.6)
  Sibutramine 70 (44.6) 24 (50.0) 7 (29.2) 39 (45.9)
  Other 61 (38.9) 16 (33.3) 2 (8.3) 43 (50.6)
Notes: Data reported as mean ± SD, n (%), or median (min–max). Total cholesterol (n = 834); LDL-c (n = 540); hDL-c (n = 541); triglycerides (n = 774); glycated hemoglobin 
(hbA1c, n = 250); systolic and diastolic blood pressure (n = 1273), without (n = 952) and with diabetes (n = 321); fasting plasma glucose (n = 872), with (n = 302) and without 
(n = 570) diabetes, without diabetes or pre-diabetes (n = 510).
Abbreviations: ARBs, angiotensin ii receptor blocker; Acei, angiotensin converting enzyme inhibitor; ccB, calcium channel blocker; hDL-c, high-density lipoprotein   
cholesterol; LDL-c, low-density lipoprotein cholesterol.
Excess body weight was identified as a health problem 
by the majority of patients (81.4%). More than half (65.2%) 
had sought medical attention for this problem on at least one 
occasion. About half (48.4%) had made significant efforts to 
lose weight during the previous three months. This feature 
was more common among patients seeing an endocrinologist 
(P = 0.002). No difference in weight loss occurred between 
specialist groups.
The majority of the patients (89%) had the intention to 
follow a dietary program with or without the advice of their 
physician. The endocrinologist asked patients to follow a 
dietary program more often than other specialists (79.6% vs 
61.9%, P , 0.001). The endocrinologists prescribed the 
dietary program themselves to about half their patients and 
requested the participation of a nutritionist in 33.2% of cases. 
The other health professionals were less likely to give dietary 
advice or seek the advice of a nutritionist (Table 3).
The majority of patients (84%) were asked to increase 
their level of physical activity. The physicians themselves 
prescribed the physical activity program in close to 40% 
of patients from all three physician groups. No differences 
were observed between groups, in the percentage of patients 
exercising and the duration of physical activity at baseline. 
Weight control drugs were used by a small percentage of 
the patients (12.1%); sibutramine (5.4%) was most popular, 
followed by orlistat (2.5%). Less than one-quarter of the 
patients on weight control medication had been on it for 
more than three months; this percentage did not vary between 
specialist groups.
high blood pressure
The prevalence of high blood pressure was 63.4% (n = 703). 
The agreement between physician-diagnosis and patients 
recalled for arterial hypertension was moderate (kappa = 0.62). 
High blood pressure was diagnosed 5.9 ± 7.2 years before 
inclusion into the study. Patients under the care of the 
cardiologists had significantly higher systolic and diastolic 
pressures (P , 0.001, Table 2). Only 63.4% of patients with 
high blood pressure were receiving drug therapy. At the time of 
evaluation, few of them had reached target values for diastolic 
(24.1%) and systolic/diastolic (13.3%) pressure. The most 
frequent antihypertensive drugs were angiotensin II receptor Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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Figure 1 number of cardiometabolic risk factors (dyslipidemia, hypertension, type 2 diabetes, and cardiovascular disease) at different waist circumference strata in 
men and women.
blockers, diuretics, beta-blockers, and calcium channel 
blockers. Their use did not differ between specialists.
Dyslipidemia
The prevalence of dyslipidemia was 60.4% (n = 703) (Table 2). 
The agreement between physician-diagnosis and patients 
recalled for dyslipidemia was low (kappa = 0.36). Plasma 
lipid levels were available in 78% of the patients. The primary 
care physicians requested lipid measurements less often than 
the other two groups. Abnormal lipid concentrations were 
diagnosed 2.2 ± 4.1 years before inclusion into the study. 
Patients under the care of the cardiologists had significantly 
higher total cholesterol, LDL-c, and triglyceride concentrations 
(P , 0.001, Table 2). The prevalence of total cholesterol levels 
$5.2 mmol/L was 44.4%; this percentage was significantly 
greater in patients under the care of the cardiologists (50.7%, 
P = 0.009). The prevalence of hypertriglyceridemia was 55.3%; 
this abnormality was also more frequent in patients who   Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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were being attended by the cardiologists (61.8%). Low HDL-c   
values were found in 55.2% of men and 67.2% of women. 
Less than half of the patients with dyslipidemia were   
receiving drug therapy. A greater percentage of the patients 
under cardiologist care were on lipid-lowering therapy 
compared to the other two groups (Table 2). Statins were the 
most frequently used drug (76.5%). The use of lipid-lowering 
medications did not differ between specialists. Only a small 
proportion of the patients on lipid-lowering medication were 
at their LDL-c targets (32.2%).
Table 3 Summary of the interventions stratified by physician specialty
Indication N All group  
(n = 1312)
Patients treated by  
internists/general  
practitioners  
(n = 384)
Patients treated  
by cardiologist  
(n = 428)
Patients treated  
by endocrinologist/ 
diabetologist  
(n = 500)
Physical activity (PA)
  Patients asked to increase PA 1070 899 (84.0) 271 (86.0) 272 (81.7) 356 (84.4)
  Patient’s intention to increase PA 170 139 (81.8) 38 (86.4) 50 (82.0) 51 (78.5)
  Person responsible for increase PA 1070 974 (100) 296 (100) 302 (100) 376 (100)
    Patient him/herself 974 251 (25.8) 82 (27.7) 85 (28.1) 84 (22.3)
    Dietician/nutritionist 974 77 (7.9) 21 (7.1) 21 (7.0) 35 (9.3)
    general practitioner/internist 974 210 (21.6) 129 (43.6) 33 (10.9) 48 (12.8)
    cardiologist 974 179 (18.4) 15 (5.1) 144 (47.7) 20 (5.3)
    endocrinologist 974 166 (17.0) 18 (6.1) 1 (0.3) 147 (39.1)
    Other 974 91 (9.3) 31 (10.5) 18 (6.0) 42 (11.2)
  Patient currently practising PA 1070 733 (68.5) 223 (70.8) 214 (64.3) 296 (70.1)
    Minutes within last week 733 732 (100) 222 (100) 214 (100) 296 (100)
   # 60 732 154 (21.0) 43 (19.4) 49 (22.9) 62 (20.9)
   60.1–90 732 85 (11.6) 32 (14.4) 20 (9.3) 33 (11.1)
   90.1–120 732 95 (13.0) 26 (11.7) 23 (10.7) 46 (15.5)
   . 120 732 398 (54.4) 121 (54.5) 122 (57.0) 155 (52.4)
  Reason for practising PA 732 732 (100) 222 (100) 214 (100) 296 (100)
  To lose weight 732 463 (63.3) 146 (65.8) 120 (56.1) 197 (66.6)
  Diabetes 732 158 (21.6) 39 (17.6) 40 (18.7) 79 (26.7)
  Dyslipidemia 732 133 (18.2) 38 (17.1) 40 (18.7) 55 (18.6)
  hypertension 732 209 (28.6) 47 (21.2) 93 (43.5) 69 (23.3)
  heart/vascular condition 732 57 (7.8) 13 (5.9) 31 (14.5) 13 (4.4)
  Other 732 217 (29.6) 70 (31.5) 59 (27.6) 88 (29.7)
Weight 1070 1070 (100) 315 (100) 333 (100) 422 (100)
  Weight problem 1068 869 (81.4) 248 (79.0) 262 (78.9) 359 (85.1)
  health professional consulted 1070 698 (65.2) 187 (59.4) 177 (53.2) 334 (79.1)
  Significant effort to lose weight 1062 514 (48.4) 145 (46.6) 140 (42.2) 229 (54.7)
  Weight lost (last 3 months) 652 3 (0–32) 3 (0–26) 3 (0–32) 3 (0–20)
  Lowest weight (last 6 months) 1010 81.7 ± 17.2 79.1 ± 15.7 83.5 ± 17.8 82.2 ± 17.5
  highest weight (last 6 months) 1029 88.1 ± 18.9 85.4 ± 17.0 88.9 ± 19.6 89.4 ± 19.5
  Surgery for reducing weight 1064 11 (1.0) 5 (1.6) 2 (0.6) 4 (1.0)
Diet 1070 1070 (100) 315 (100) 333 (100) 422 (100)
  Patients asked to follow a diet 1070 720 (67.3) 195 (61.9) 189 (56.8) 336 (79.6)
  Patient’s intention to follow a diet 337 300 (89.0) 105 (90.5) 123 (89.1) 72 (86.7)
  Patient currently following a diet 1063 722 (67.9) 200 (63.9) 199 (59.9) 323 (77.3)
  Reason to follow a diet 1070 722 (100) 200 (100) 199 (100) 323 (100)
  To lose weight 722 522 (72.3) 146 (73.0) 128 (64.3) 248 (76.8)
  Diabetes 722 190 (26.3) 50 (25.0) 43 (21.6) 97 (30.0)
  Dyslipidemia 722 162 (22.4) 43 (21.5) 53 (26.6) 66 (20.4)
  hypertension 722 187 (25.9) 42 (21.0) 85 (42.7) 60 (18.6)
  heart/vascular condition 722 57 (7.9) 7 (3.5) 28 (14.1) 22 (6.8)
  Other 722 129 (17.9) 38 (19.0) 29 (14.6) 62 (19.2)
  Frequency patient followed diet 722 709 (100) 195 (100) 198 (100) 316 (100)
  Always 709 208 (29.3) 49 (25.1) 64 (32.3) 95 (30.1)
  Most of the time 709 313 (44.1) 97 (49.7) 72 (36.4) 144 (45.6)
  Some of the time 709 127 (17.9) 33 (16.9) 40 (20.2) 54 (17.1)
  A little of the time 709 50 (7.1) 14 (7.2) 19 (9.6) 17 (5.4)
  never 709 11 (1.6) 2 (1.0) 3 (1.5) 6 (1.9)Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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Type 2 diabetes
The prevalence of type 2 diabetes was 22% (n = 289). The 
agreement between physician-diagnosis and patients recalled 
for diabetes was moderate (kappa = 0.87). Type 2 diabetes 
was diagnosed 6.4 ± 7.4 years before inclusion into the 
study. Patients attended by endocrinologists had the highest 
diabetes prevalence (31%, P , 0.001, Table 2). The majority 
of patients (92.6%) were receiving drug therapy. The most 
frequently used drugs were metformin and sulfonylureas. 
Insulin was used by 14.7% of the patients with diabetes. The 
mean fasting plasma glucose level was 8.9 ± 3.4 mmol/L. Half 
of the patients with diabetes (52.2%) had an AMA = HbA1c 
measurement. Almost half of the diagnosed cases had an 
HbA1c , 7%. This percentage was higher in those under 
endocrinologist care (64.6%, P , 0.001). At the time of 
evaluation, only a few of these patients were at optimal levels 
of diastolic (27.4%) and systolic (43.0%) pressures. Diabetes 
related chronic complications were common in the study 
sample. The most common microvascular complications 
were sensitive polyneuropathy (71%) followed by retinopathy 
(27.5%) and nephropathy (23.2%). In addition, 19% had had 
a cardiovascular complication.
cardiovascular disease
This category includes all patients who had suffered a 
myocardial infarction, unstable angina, transient ischemic 
attack, peripheral artery disease, revascularization, or any 
other clinical manifestation caused by coronary artery 
disease. The prevalence of cardiovascular disease was 
14.4% (n = 184). The agreement between physician-
diagnosis and patients recalled for cardiovascular disease 
was moderate (kappa = 0.47). Cardiovascular disease was 
diagnosed 8.4 ± 10.5 years before inclusion into the study. 
Patients under the care of cardiologists had the highest 
prevalence (23.6%, P , 0.001, Table 2). The majority of 
patients (72.9%) treated by cardiologists were receiving 
medication. This was not true for the other two groups 
(primary care physicians 38%, endocrinologists 33.5%). 
Few patients were at treatment targets. Only 32.2% had an 
LDL cholesterol ,2.6 mmol/L, 49% were at blood pressure 
targets, 39.4% had triglycerides ,1.6 mmol/L, and 38.6% 
had the recommended HDL cholesterol concentrations.
The social and medical burden  
of abdominal obesity
The quality of life of patients was good with a mean score 
in the EQ-5D survey of 0.8 ± 0.2 points (n = 1070). A 
small percentage (6.4%) of patients referred to themselves 
as disabled due to illness and unable to work. No mood 
abnormalities were reported by 64.1% of patients. How-
ever, 38.6% (n = 413) and 4.1% (n = 44) reported moderate 
or extreme discomfort caused by their illness, respectively   
(Table 4).
covariates associated with  
obesity-related comorbidities
Logistic regression models were constructed to identify 
variables associated with each of the comorbidities (Table 5). 
Waist circumference was independently associated with 
high blood pressure and HbA1c in patients with diabetes. 
Borderline significance was found for the association of 
waist circumference and hypertriglyceridemia (P = 0.077) 
and hypoalphalipoproteinemia (P = 0.056) respectively. 
No association was found between waist circumference and 
fasting glycemia, presence of cardiovascular disease, and the 
occurrence of two or more cardiometabolic risk factors.
Discussion
Over the past 40 years, excess body weight has become 
a major health problem in Mexico.13 However, not every 
case has comorbidities that affect the quality of life and life 
expectancy.14 Health systems worldwide are not prepared 
to face the ongoing obesity epidemic. Many patients and 
physicians are not aware of the health risks associated with 
abdominal obesity.15 It is a requirement not only to design 
effective obesity treatment programs but also to have an 
adequate description of the characteristics of the target 
population. This information cannot be obtained from 
population-based surveys or institutional databases because 
these sources include individuals seeking treatment for 
various medical conditions or those not looking for therapy at 
all. Our study describes the medical care given to individuals 
with abdominal obesity during daily clinical practice by 
general practitioners, cardiologists, and endocrinologists. 
It was designed to provide data representative of the pattern 
of care that patients with abdominal obesity receive in 
urban Mexico. Our data confirm that a large proportion 
of patients are undertreated. Only a small percentage 
of patients with obesity-related comorbidities reach 
treatment targets. Interventions proven to be effective in 
the prevention of chronic complications have in general not 
been implemented.
The study population is representative of patients treated 
by specialists who are usually involved in the management of 
abdominal obesity. Precautions were taken to avoid potential 
selection bias by the physicians. This approach allowed Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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Table 4 The social and medical burden of abdominal obesity
N All group  
(n = 1312)
Patients treated by  
internists/general  
practitioners  
(n = 384)
Patients treated  
by cardiologist  
(n = 428)
Patients treated  
by endocrinologist/ 
diabetologist  
(n = 500)
Smoking habits 1070 1070 (100) 315 (100) 333 (100) 422 (100)
  never smoked 1070 554 (51.8) 170 (54.0) 178 (53.5) 206 (48.9)
  Smoked in the past 1070 320 (29.9) 92 (29.2) 107 (32.1) 121 (28.7)
  currently smoking 1070 196 (18.3)  53 (16.8) 48 (14.4) 95 (22.5)
  Alcohol consumption (per day) 1070  1063 (100)  314 (100) 328 (100) 421 (100)
  none or less than 1 glass 1063 1012 (95.2) 298 (94.9) 308 (93.9) 406 (96.4)
  1–2 glasses 38 (3.6) 13 (4.1) 13 (4.0) 12 (2.9)
  3 or more glasses 13 (1.2) 3 (0.9) 7 (2.1) 3 (0.7)
health insurance 1068 1068 (100) 314 (100) 333 (100) 421 (100)
  Public  – 418 (39.1) 112 (35.7) 140 (42.0) 166 (39.4)
  Private – 270 (25.3) 101 (32.2) 76 (22.8) 93 (22.1)
  Public + private – 92 (8.6) 29 (9.2) 29 (8.7) 34 (8.1)
  none – 280 (26.2) 72 (22.9) 86 (25.8) 122 (29.0)
  Don’t know – 8 (0.7) 0 (0.0) 2 (0.6) 6 (1.4)
employment status 1066 1066 (100) 313 (100) 331 (100) 422 (100)
  Full time job – 443 (41.6) 133 (42.5) 136 (41.1) 174 (41.2)
  Part time job – 186 (17.4) 62 (19.8) 43 (13.0) 81 (19.2)
  not employed – 437 (41.0) 118 (37.7) 152 (45.9) 167 (39.6)
Level of education 1068 1068 (100) 315 (100) 332 (100) 421 (100)
  none – 24 (2.2) 7 (2.2) 12 (3.6) 5 (1.2)
  Primary level – 157 (14.7) 33 (10.5) 70 (21.1) 54 (12.8)
  Secondary level/high school – 215 (20.1) 68 (21.6) 73 (22.0) 74 (17.6)
  college/university – 672 (62.9) 207 (65.7) 177 (53.3) 288 (68.4)
us to detect problems in both diagnostic and therapeutic 
actions. Our survey identified multiple conceptual and 
logistic challenges in the management of patients with 
abdominal obesity. Although all patients had abdominal 
obesity, less than half identified this as the main reason 
for the medical consultation. Half of the study population 
(48.4%) mentioned that they had made significant efforts 
to lose weight over the previous three months. However, 
the mean weight lost was moderate (4.3 ± 3.5 kg). A small 
proportion of physicians requested the participation of a 
nutritionist to provide dietary advice. In many cases, the 
specialist offered no dietary modification. The majority of 
patients (84%) were asked to increase their physical activity. 
However, less than half reported more than 120 minutes of 
physical activity per week.
Our observations confirm that the treatment of abdominal 
obesity is complex and unsatisfactory.16 Modification of life-
style is a remarkable challenge for adults. Physicians should 
be highly motivated to create awareness of the disease in 
patients and their relatives. In addition, they should educate 
and train patients to modify their dietary habits and to increase 
physical activity on a long-term basis. Health systems around 
the world should change their procedures and priorities to 
effectively face the epidemic in abdominal obesity.17,18
Increased waist circumference is a predictor for the 
presence of obesity-related comorbidities. As a conse-
quence, the treatment of abdominal obesity should not be 
limited to inducing weight loss. The adequate management 
of comorbidities is a prime component of therapy. Each of 
these interventions is effective in reducing the risk of long-
term obesity related complications.19–21 Despite this, current 
treatment targets are achieved in only a small proportion 
of cases (Tables 2 and 3). Our results are similar to others 
reported worldwide.22 Clinical inertia, lack of awareness in 
patients and physicians, and limited resources are some of 
the reasons for this finding.23 Structured programs designed 
to improve the quality of care of patients with diabetes and 
cardiometabolic risks are urgently needed.
Scant information exists regarding the social burden caused 
by abdominal obesity.24 The quality of life of patients was good, 
with a mean score in the EQ-5D survey of 0.8 ± 0.2 points. 
Despite this, 38.6% and the 4.1% referred to moderate or 
extreme discomfort caused by their illness, respectively. Thus, 
abdominal obesity should not be considered as only a medical 
problem. Social, economic, and psychological phenomena are 
the underlying factors. Medical personnel should be prepared 
to help patients overcome the environmental barriers that 
preclude them from having a healthy lifestyle.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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Table 5 Logistic regression analyses to evaluate the association 
between waist circumference, BMi, age, and gender with the risk 
factors studied
Parameter  OR (CI 95%) P value
hypertriglyceridemia
  Female vs male 0.55 (0.41–0.74) ,0.0001
Low hDL-c
  BMi $ 30 vs # 27 kg/m2 3.2 (1.95–5.55) ,0.0001
  Female vs male 1.6 (1.12–2.30) 0.009
hypertension
  Wc 100–105 vs 80–85 cm 0.28 (0.13–0.62) 0.0209
  Wc $ 110 vs 80–85 cm 0.23 (0.11–0.50) ,0.0001
  Age , 65 vs $ 65 years 1.76 (1.29–2.40) 0.0003
Fasting plasma glucose
  Wc 100–105 vs 80–85 cm 4.40 (1.27–15.2) 0.0225
  Wc $ 110 vs 80–85 cm 5.74 (1.70–19.3) ,0.0001
  Age , 65 vs $ 65 years 0.66 (0.45–0.98) 0.0391
Type 2 diabetes
  Wc 105–110 vs 80–85 cm 4.43 (1.57–12.5) 0.02
  Wc $ 110 vs 80–85 cm 5.78 (2.07–16.1) ,0.0001
  BMi $ 30 vs # 27 kg/m2 0.54 (0.34–0.86) 0.0078
  Age , 65 vs $ 65 years 0.55 (0.40–0.77) 0.0005
cardiovascular disease
  Female vs male 0.49 (0.35–0.68) ,0.0001
Two or more risk factors
  Wc $ 110 vs 80–85 cm 3.81 (1.31–11.05) 0.0024
  Age , 65 vs $ 65 years 0.36 (0.26–0.50) ,0.0001
  Female vs male 0.72 (0.54–0.96) 0.0268
Note: Only significant results are shown.
Abbreviations:  BMi,  body  mass  index;  Wc,  waist  circumference; 
hDL-c, high-density lipoprotein cholesterol.
The cross-sectional design and the lack of a control group 
without abdominal obesity are the main limitations of this 
report. Both defects limit our ability to confirm the known 
linear association that exists between waist circumference and 
the number and severity of each one of the cardiometabolic 
risks. Also, the approach used to assess dietary habits and 
physical activity may have a low sensitivity and significant 
variability.25 In addition, information on other features of 
the metabolic syndrome (eg, fatty liver, chronic kidney 
disease, polycystic ovarian disease, hyperuricemia, and 
obstructive sleep apnea) was not registered. Finally, we 
concentrated on the management of abdominal obesity and 
its complications. We did not place emphasis on the diabetes-
related microvascular complications because abdominal 
obesity is not a major risk factor for these outcomes.
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